Article thumbnail

The Level of Isoprostanes as a Non-invasive Marker for in vivo Lipid Peroxidation in Secondary Progressive Multiple Sclerosis

By Elżbieta Miller, Małgorzata Mrowicka, Joanna Saluk-Juszczak and Majsterek Ireneusz

Abstract

Oxidative stress leads to lipid peroxidation and may contribute to the pathogenesis of lesions in multiple sclerosis (MS), an autoimmune disease characterized by inflammatory as well as degenerative phenomena. Isoprostanes are prostaglandin-like compounds which are formed by free radical catalysed peroxidation of arachidonic acid esterified in membrane phospholipids. They are a new class of sensitive specific markers for in vivo lipid peroxidation. In this study 26 patients (15 females and 11 males; mean age 48.2 ± 15.2 year; mean disease duration 10.0 ± 6.5 year) with secondary progressive MS (SPMS) and 12 healthy controls were enrolled. In patients with multiple sclerosis the lipid peroxidation as the level of urine isoprostanes and the level of thiobarbituric acid reactive species (TBARS) in plasma were estimated. Moreover, we estimated the total antioxidative status (TAS) in plasma. It was found that the urine isoprostanes level was over 6-fold elevated in patients with SPMS than in control (P < 0.001). In SPMS patients TBARS level was also statistically higher than in controls (P < 0.01). However, we did not observed any difference of TAS level in serum between SPMS patients and controls (P > 0.05). In patients with SPMS the lipid peroxidation and oxidative stress measured as the increased level of isoprostanes was observed. Thus, we suggest that the level of isoprostanes may be used as non-invasive marker for a determination of oxidative stress what in turn, together with clinical symptoms, may determine an specific antioxidative therapy in SPMS patients

Topics: Original Paper
Publisher: Springer US
OAI identifier: oai:pubmedcentral.nih.gov:3084932
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). Altered lipid metabolism in brain injury and disorders.
  2. (2008). Apoptic matkers in human blood platelets treated with peroxynitrite.
  3. (1996). Defining the clinical course of multiple sclerosis results of an international survey.
  4. (2004). Development of biomarkers in multiple sclerosis.
  5. (2000). Effects of isoprostanes on sympathetic neurotransmission in the human isolated iris-ciliary body.
  6. (2010). Effects of whole body cryotherapy on a total antioxidative status and activity of antioxidant enzymes in blood of depressive multiple sclerosis patients. World J biol Psychiatry [Epub a head of print]
  7. (2007). Elevated cerebrospinal fluid F2- isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients.
  8. (2000). Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases.
  9. (2004). Isoprostanes: novel bioactive products of lipid peroxidation.
  10. (2010). Lower levels of gluthatione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3T. Mult Scler [Epub ahead of print]
  11. Malinowska et al (2010) Effects of whole body cryotherapy on oxidative stress in multiple sclerosis patients.
  12. Malinowska et al (2010) Effects of whole body cryotherapy on total antioxidative status and activities of antioxidative enzymes in blood of patients with multiple sclerosis.
  13. (2011). Multiple sclerosis. In: Shamim I Ahmad. Neurodegenerative diseases. Springer Lands Bioscience.
  14. (2010). Nitrosative stress in the brain: autoantibodies to nitrotyrosine in liquor as a potential marker.
  15. (2008). Oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis? Mult Scler 14:22–34
  16. (2007). Plasma lipid peroxidation and progression of disability in mutiple sclerosis.
  17. (2008). Secondary progressive multiple sclerosis-clinical course and potential predictive factors.
  18. (2002). Serum levels of antioxidant vitamins and lipid peroxidation in multiple sclerosis.
  19. (2006). The isoprostanes–unique products of arachidonate peroxidation: their role as mediators of oxidant stress.
  20. (2004). The role of oxidative stress in the pathogenesis of multiple sclerosis. The need for the effective antioxidant therapy.